Navigation Links
Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
Date:5/14/2012

ROCHESTER, Minn. -- Alterations to the "on-off" switches of genes occur early in the development of prostate cancer and could be used as biomarkers to detect the disease months or even years earlier than current approaches, a Mayo Clinic study has found. These biomarkers known as DNA methylation profiles also can predict if the cancer is going to recur and if that recurrence will remain localized to the prostate or, instead, spread to other organs. The study, published in the journal Clinical Cancer Research, is the first to capture the methylation changes that occur across the entire human genome in prostate cancer.

The discovery could someday help physicians diagnose prostate cancer earlier and make more effective treatment decisions to improve cure rates and reduce deaths. It also points to the development of new drugs that reverse the DNA methylation changes, turning the "off" switch back "on" and returning the genetic code to its normal, noncancerous state.

"Our approach is more accurate and reliable than the widely used PSA (prostate-specific antigen) test," says senior author Krishna Donkena, Ph.D., a Mayo Clinic molecular biologist.

The PSA test detects any prostate abnormality, whether inflammation, cancer, infection or enlargement, while the DNA methylation changes are specific to prostate cancer, she says.

Though the instructions for all the cell's activities lie within the genes, whether a particular gene is turned "off" or "on" is determined by the presence or absence of specific chemical tags or methyl groups methylation along the underlying DNA of cells. When this process of DNA methylation turns off the activity of tumor suppressor genes, cancer develops.

Dr. Donkena and her colleagues analyzed the methylation status of 14,495 genes from 238 prostate cancer patients. The patients included people who remained cancer-free after treatment, those who had a localized tumor recurrence and those whose cancer spread. The researchers found that the DNA methylation changes that occurred during the earliest stages of prostate cancer development were nearly identical in all patients.

Having discovered DNA methylation patterns that could distinguish between healthy and cancerous tissue, the researchers then searched for similar biomarkers that could distinguish between patients with varying levels of recurrence risk. They found distinct methylation alterations that corresponded to whether a patient had a slow-growing tumor known as an indolent tumor, or had a more aggressive one.

If physicians can determine what type of tumor patients have, they can avoid exposing patients with indolent tumors to unnecessary treatment, and can treat those with aggressive tumors earlier and more effectively, Dr. Donkena says.

Dr. Donkena and her colleagues are working to develop a DNA methylation test that is more cost-effective and practical for use in clinical settings. Currently, the test relies on microarray or gene "chip" technology that assesses methylation status of genes across an entire genome. The researchers are trying to generate more economical custom microarray to specifically look at only the genes that predict the development of prostate cancer or recurrence.

They also hope to develop drugs that can reverse DNA methylation in prostate cancer cells. Similar drugs are already being used to treat certain forms of leukemia.


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Automated insulin dosage titration system demonstrates positive clinical study results
2. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
3. Analysis Finds Clinical Trials Often Small, of Poor Quality
4. URMC clinical trial tests new regimen for hypertension
5. Mayo Clinic: Obesity epidemic fueling rise in rheumatoid arthritis among women
6. Association for Psychological Science, SAGE launch Clinical Psychological Science
7. Awards celebrate clinical research that can improve health and alleviate suffering
8. Kroenke honored for outstanding contributions in clinical research training
9. Mayo Clinic breast cancer study finds new type of mutation
10. NYU Langone experts present research, clinical advances at neurosurgeons meeting
11. Mayo Clinic offers newly approved treatment for acid reflux disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Erlanger Agency has announced a new partnership in ... latest campaign focuses on the fight against breast cancer, fundraising for a local woman ... here . , Carmen is a loving single mother of two boys who also ...
(Date:2/12/2016)... ... , ... Miami Dental Specialists is excited to bring patients the choice of ... January, Miami Dental Specialists will offer the non-metal implants as a safe, holistic and ... chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge technology to Miami. ...
(Date:2/12/2016)... York, NY (PRWEB) , ... February 12, 2016 ... ... edition of “Revolutionizing Cancer Care.” , The print component of “Revolutionizing ... Chicago, Dallas, Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners ... exterior design possibilities. CertainTeed, North America’s leading brand of building products, has improved ... offerings showcased in the mobile version of the ColorView® Exterior Style and Color ...
(Date:2/12/2016)... ... February 12, 2016 , ... Healthcare careers in the medical laboratory, nursing, ... via the website of healthcare staffing leader Aureus Medical Group during the month of ... travel therapy positions and in travel and direct hire opportunities in other ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Inc. (NYSE: DPLO ) is pleased to announce the promotion of Paul Urick ... 23, 2016. To learn more about our ... ... ... In his redefined ...
(Date:2/12/2016)... 12, 2016   HeartWare International, Inc . (NASDAQ: ... webcast to discuss its financial results for the three ... February 25, 2016 at 8:00 a.m. ET.  The company ... conference call and webcast.  On the conference call and ... from the fourth quarter and business outlook.   ...
(Date:2/12/2016)... 12, 2016  Sequent Medical, Inc. announced today that ... evaluate the safety and effectiveness of the WEB™ Aneurysm ... intracranial aneurysms.  Prof Laurent Spelle , MD, Head ... Paris, France and Principal Investigator of the ... France and Germany.  Although patients with ruptured ...
Breaking Medicine Technology: